Summary and impact of ovarian cancer research and programmatic activities at the centers for disease control and prevention

Journal of Women's Health

Volumn 19, Issue 8, 2010, Pages 1427-1432

  Stewart, Sherri L ^a   Rim, Sun Hee ^a   Trivers, Katrina F ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RESEARCH; EVALUATION; FEMALE; HEALTH PROGRAM; HEALTH SERVICES RESEARCH; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW;

ATTITUDE TO HEALTH; BIOMEDICAL RESEARCH; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; OVARIAN NEOPLASMS; POPULATION SURVEILLANCE; SEER PROGRAM; UNITED STATES;

EID: 77955253605     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2010.2164     Document Type: Review

References (33)

1. U.S. Cancer Statistics Working Group. United States Cancer Statisics, 1999-2006. Incidence and mortality web-based report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2010.
2. Eheman CR, Peipins L, Wynn M, et al. Development of a public health research program for ovarian cancer. J Womens Health 2006;15:339-345.
3. Trivers KF, Stewart SL, Peipins L, Rim SH, White MC. Expanding the public health research agenda for ovarian cancer. J Womens Health 2009;18:1299-1305.
4. Major A, Stewart SL. Celebrating 10 years of the National Comprehensive Cancer Control Program, 1998 to 2008. Prev Chronic Dis 2009;6:A133.
5. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control-A comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 2003;14:175-193.
6. Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 2003; 97(Suppl 10):2615-2630.
7. Hall HI, Tung KH, Hotes J, Logan P. Regional variations in ovarian cancer incidence in the United States, 1992-1997. Cancer 2003;97(Suppl 10):2701-2706. (Pubitemid 36539071)
8. Stewart SL, Thompson TD, German RR, Cardinez CJ, Friedman C, Wingo PA. Geographic patterns of gynecologic cancer incidence and mortality. J Clin Oncol 2005;23(Suppl): 477S.
9. Stewart SL, King JB, Cardinez CJ, Thompson TD, Friedman C, Wingo PA. Geographic patterns of breast and ovarian cancer incidence and mortality. Cancer Epidemiol Biomarkers Prev 2004;13:1868S.
10. Stewart SL, Wike JM, Sabatino SA. Recent declines in ovarian cancer incidence rates in the United States. Proc AACR Frontiers in Cancer Prevention Res 2007:A53.
11. CDC. Decline in breast cancer incidence-United States, 1999-2003. MMWR 2007;56:549-553.
12. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007;107:392-397.
13. Gershenson DM. Fallopian tube cancer: Stepchild or mother? Gynecol Oncol 2007;107:386-387.
14. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9. (Pubitemid 46095865)
15. Hall HI, Jamison P, Weir HK. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 2001;10:995-999.
16. Rim SH, Berkowitz Z, Peipins L. Ovarian as a subsequent primary among women cancer survivors, 1973-2004. Cancer Epidemiol Biomarkers Prev 2008;17:464.
17. Berkowitz Z, Rim SH, Peipins L, Stewart SL. Factors associated with survival time among women diagnosed with ovarian as an index cancer versus a subsequent primary. Am J Epidemiol 2009;169:S4.
18. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(Suppl 8):IV-18.
19. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 2007; 109:1053-1061.
20. Wynn ML, Chang S, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. J Womens Health 2007;16:971-986.
21. Stewart SL, Wike JM, Cress R, OMalley C, Neloms S, Kahn AR, Schymura MJ. Ovarian cancer treatment patterns and outcomes in the United States: a National Program of Cancer Registries Study. J Clin Oncol 2006;24(Suppl):15031.
22. Cress RD, Bauer K, OMalley CD, et al. Surgical staging of early-stage epithelial ovarian cancer. Gynecol Oncol 2009;112:S154.
23. Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010;116:1462-1468.
24. Stewart SL, Thompson TD, Wike JM, et al. Descriptive epidemiology, treatment, and survival of low-grade and highgrade serous adenocarcinoma of the ovary. Gynecol Oncol 2009;112:S24.
25. Stewart SL, Wike JM, Cress RD, OMalley CD, Kahn AR, Schymura MJ. Treatment patterns and outcomes of ovarian cancer patients by histology, data from the National Program of Cancer Registries (NPCR) Patterns of Care Study. Proc North Am Assoc Central Cancer Registries 2006:P-04.
26. Rolnick SJ, Jackson J, Nelson WW, et al. Pain management in the last six months of life among women who died of ovarian cancer. J Pain Symptom Manage 2007;33:24-31.
27. Herrinton LJ, Neslund-Dudas C, Rolnick SJ, et al. Complications at the end of life in ovarian cancer. J Pain Symptom Manage 2007;34:237-243.
28. Jackson JM, Rolnick SJ, Coughlin SS, et al. Social support among women who died of ovarian cancer. Support Care Cancer 2007;15:547-556.
29. Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007;109:2031-2042.
30. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal mass. Evid Rep Technol Assess (Full Rep) 2006;130: 1-145.
31. Pollard WE. Use of consumer panel survey data for public health communication planning: An evaluation of survey results. Am Statist Assoc Proc Section Health Policy Statist 2002;2720-2724.
32. Stewart SL, Rim SH, Gelb CA. Public and provider awareness and use of a CA-125 test for ovarian cancer. Cancer Prev Res 2010;3(Suppl 1):A25.
33. U.S. Preventive Services Task Force. Screening for ovarian cancer, 2004. Available at www.ahrq.gov/clinic/uspstf/uspsovar.htm